Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10725467 | 0.89 | MEN1 (0.60) | ALDH1A1KMT2AHSD17B10MEN1GMNN | |
| SCHEMBL10725250 | 0.88 | MEN1 (0.59) | ALDH1A1KMT2AHSD17B10MEN1GMNN | |
| SCHEMBL1363026 | 0.87 | KMT2A (0.52) | ALDH1A1KMT2AHSD17B10MEN1GMNN | |
| SCHEMBL10730621 | 0.87 | MEN1 (0.50) | ALDH1A1KMT2AHSD17B10MEN1GMNN | |
| SCHEMBL6290024 | 0.87 | ALDH1A1 (0.48) | ALDH1A1KMT2AHSD17B10MEN1GMNN | |
| SCHEMBL10960565 | 0.86 | MEN1 (0.49) | ALDH1A1KMT2AHSD17B10MEN1GMNN | |
| SCHEMBL10960979 | 0.85 | ALDH1A1 (0.64) | ALDH1A1KMT2AHSD17B10MEN1GMNN | |
| SCHEMBL10961088 | 0.85 | MEN1 (0.48) | ALDH1A1KMT2AHSD17B10MEN1GMNN | |
| SCHEMBL11013350 | 0.85 | MEN1 (0.48) | ALDH1A1KMT2AHSD17B10MEN1GMNN | |
| SCHEMBL4930818 | 0.85 | KMT2A (0.53) | ALDH1A1KMT2AHSD17B10MEN1GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004201-A1 | PHOSPHODIESTARASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| EP-2346867-A1 | PHOSPHODIESTARASE INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2011-07-27 | — | — | EP | disclosed |
| EP-2046787-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2011-04-06 | — | — | EP | disclosed |
| EP-1940835-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2011-03-30 | — | — | EP | disclosed |
| EP-1581532-B1 | PYRAZOLO¬3,4-B PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LTD (GB) | 2010-04-28 | — | — | EP | disclosed |
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-4645838-A | Pyrazolopyridine compounds, and intermediates, useful as anxiolytic agents | ICI AMERICAS INC. (US) | 1987-02-24 | — | — | US | disclosed |
| EP-0094175-B1 | PYRAZOLOPYRIDINE COMPOUNDS | ICI AMERICAS INC. (US) | 1986-10-29 | — | — | EP | disclosed |
| US-4563525-A | Process for preparing pyrazolopyridine compounds | ICI AMERICAS INC. (US) | 1986-01-07 | — | — | US | disclosed |
| EP-0076035-B1 | PYRAZOLO(3,4-B)PYRIDINE DERIVATIVES | ICI AMERICAS INC. (US) | 1985-12-11 | — | — | EP | disclosed |
| US-4552883-A | CNS DEPRESSANTS, ANXIOLYTICS | ICI AMERICAS INC. (US) | 1985-11-12 | — | — | US | disclosed |
| US-4511568-A | CNS-Depressant pyrazolopyridines | ICI AMERICAS INC. (US) | 1985-04-16 | — | — | US | disclosed |
| EP-0096995-A2 | Pyrazolopyridine compounds | ICI AMERICAS INC. (US) | 1983-12-28 | — | — | EP | disclosed |
| EP-0094175-A1 | Pyrazolopyridine compounds | ICI AMERICAS INC. (US) | 1983-11-16 | — | — | EP | disclosed |
| EP-0076035-A1 | Pyrazolo(3,4-b)pyridine derivatives | ICI AMERICAS INC. (US) | 1983-04-06 | — | — | EP | disclosed |
| US-4364948-A | Pyrazolo[3,4-b]pyridine compounds | ICI AMERICAS INC. (US) | 1982-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326003-A1 | PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | ALDH1A1 692/4885KMT2A 2872/4885HSD17B10 1350/4885 |
| US-20120004201-A1 | PHOSPHODIESTARASE INHIBITORS | PDE4A, PDE7A, PDE4B | ALDH1A1 1452/4885KMT2A 3957/4885HSD17B10 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.